PPLPHARMA.NSPPLPHARMA.NSNSE
Loading
EBITDA Margin Over TimeStable
Percentile Rank25
3Y CAGR-7.2%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
-7.2%/yr
Annual compound
Percentile
P25
Within normal range
vs 3Y Ago
0.8x
Contraction
Streak
1 yr
Consecutive declineStable
PeriodValueYoY Change
202515.34%-8.3%
202416.73%+40.0%
202311.95%-37.8%
202219.21%-12.8%
202122.03%-